Abstracts tagged "prognostic factors"

Abstract Number: 2558 • ACR Convergence 2024
Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand
Patapong Towiwat¹, Wichittra Tassaneeyakul², Suppachai Lawanaskol³, Chonlaphat Sukasem⁴, Nontaya Nakkam², Ticha Rerkpattanapipat⁴, Jettanong Klaewsongkram⁵, Pawinee Rerknimitr⁵, Duangkamon Poolpun⁶, Worawit Louthrenoo⁷ and Niwat Saksit⁸, ¹Naresuan university, Phitsanulok, Thailand, ²Khon Kaen university, Khon Kaen, Thailand, ³Chaiprakan hospital, Chiang Mai, Thailand, ⁴Mahidol university, Bangkok, Thailand, ⁵Chulalongkorn university, Bangkok, Thailand, ⁶Buddhachinaraj hospital, Phitsanulok, Thailand, ⁷Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁸Phayao university, Phayao, Thailand
Background/Purpose: Severe allopurinol hypersensitivity (SAH), although uncommon, is a serious adverse event of allopurinol. Both genetic (HLA-B*58:01) and non-genetic factors (female gender, age ≥60-65 years,…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 2048 • ACR Convergence 2024
Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
Maximilian Gysan¹, Svitlana Pochepnia², Helmut Prosch², Antje Lehmann¹, Silvia Lee¹, Andreas Renner¹, Daniela Gompelmann³, Marco Idzko¹, Iris Aykara⁴, Karolina Anderle⁴, Peter Weber⁴, Hans Kiener⁴, Michael Bonelli⁴, Daniel Mrak⁴, Daniel Aletaha⁵, Helga Lechner-Radner⁴ and Kastriot Kastrati⁴, ¹Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ²Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria., Vienna, Austria, ⁴Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: The prognostic value of bronchoalveolar lavage (BAL) in connective tissue disease-related interstitial lung disease (CTD-ILD) is currently underexplored, resulting in a lack of understanding…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: 0738 • ACR Convergence 2024
Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA
Colm Kirby¹, Rachael Flood¹, Sharon Cowley², Emma Finlay³, Ronan Mullan¹, Grainne Murphy⁴ and David Kane⁵, ¹Tallaght University Hospital, DUBLIN, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³School of Biotechnology, Dublin City University, Dublin, Ireland, ⁴Cork University Hospital, Cork, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland
Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…
Abstract Number: 2083 • ACR Convergence 2024
A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy
Yun Kyu Kim¹, Ju yeon Kim², Jung Yoon Pyo³, Min Jung Kim⁴, Jin Kyun Park⁵, Eun Young Lee⁶, Yun Jong lee³, eun Bong Lee¹ and Jun Won park², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ³Seoul National University Bundang Hospital, Seongnam-si, ⁴Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ⁵Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁶3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies have demonstrated that idiopathic inflammatory myopathy (IIM) is associated with an elevated cancer risk. However, there is limited evidence on the specific…
Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jessica Neely¹, Peter Shrader², Stacey Tarvin³, Kaveh Ardalan⁴, Susan Shenoi⁵, Adam Huber⁶, Susan Kim⁷ and Hanna Kim⁸, and for the CARRA Registry Investigators, ¹UCSF, San Francisco, CA, ²Duke Clinical Research Institute, Durham, NC, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Duke University School of Medicine, Durham, NC, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷University of California, San Francisco, CA, ⁸National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…
Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Anisha Dua¹, Andrea Rubbert-Roth², Kerri Ford³, Stefano Fiore⁴, Lita Araujo³, Timothy Beukelman⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Northwestern University Division of Rheumatology, Chicago, IL, ²Cantonal Hospital St Gallen, St Gallen, Switzerland, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…
Abstract Number: 2099 • ACR Convergence 2024
A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis
Jean-Pierre Pelletier¹, Patrice Paiement¹, François Abram², Marc Dorais³ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l'Île-Perrot, QC, Canada
Background/Purpose: Currently, no established marker effectively stratifies knee osteoarthritis (OA) patients into subgroups. The infrapatellar fat pad (IPFP) has been proposed as a potential key…
Abstract Number: 2644 • ACR Convergence 2024
Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis
Kimberly Lakin¹, Robert Spiera², John Spivack¹, Yaxia Zhang¹, Jessica Gordon³ and dana Orange⁴, ¹Hospital for Special Surgery, New York, NY, ²Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁴Rockefeller University, New York, NY
Background/Purpose: We have previously shown that fibroblast CD34 is low and alpha-smooth muscle actin (aSMA) is high in severe diffuse cutaneous systemic sclerosis (dcSSc) skin,…
Abstract Number: 0804 • ACR Convergence 2024
Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort
Sung Hae Chang¹, Misti Paudel², Gregory McDermott³, Qianru Zhang⁴, You-Jung Ha⁵, Jeong Seok Lee⁶, Min Uk Kim⁷, Chan Ho Park⁸, Ji-Won Kim⁹, Jang Woo Ha¹⁰, Sang Wan Chung¹¹, Sung Won Lee¹², Eun Ha Kang⁵, Yeon-Ah Lee¹³, Jung-Yoon Choe¹⁴, Yong-Beom Park¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, ¹Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Harvard medical school, Cambridge, MA, ⁵Seoul National University Bundang Hospital, Seongnam, South Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, ⁹Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, ¹⁰Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, ¹¹Kyung Hee University Hospital, Seoul, Republic of Korea, ¹²Soonchunhyang University Cheonan Hospital, Seoul, South Korea, ¹³Kyung Hee University Hospital, Seoul, South Korea, ¹⁴Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ¹⁵Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁶3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ¹⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Predictors of progressive pulmonary fibrosis (PPF) in patients with rheumatoid arthritis-associated interstitial lung disease (ILD) are unclear but may be due to inflammation or…
Abstract Number: 2231 • ACR Convergence 2024
Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
Susan Bartlett¹, Orit Schieir², Marie-France Valois¹, Louis Bessette³, Janet Pope⁴, Gilles Boire⁵, Carol Hitchon⁶, Ed Keystone⁷, Carter Thorne⁸, Diane Tin⁸, Glen Hazlewood⁹, Hugues Allard-Chamard¹⁰, Bindee Kuriya¹¹, Vivian Bykerk¹² and Clifton Bingham¹³, and Investigators with the Canadian Early Arthritis Cohort (CATCH), ¹Centre for Outcomes Research & Eval, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³University of Laval, Quebec City, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Sherbrooke, Sherbrooke, QC, Canada, ¹¹University of Toronto - Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Johns Hopkins University, Baltimore, MD
Background/Purpose: Growing evidence suggests that across chronic diseases, patients with co-occurring symptoms of pain, anxiety, and depression (PAD), known as “symptom clusters”, experience variable disease…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0814 • ACR Convergence 2024
Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Xinzhuang Yang², Yu Fang Ding³, qian wang¹, Jiuliang Zhao¹, Weida Liu⁴, Yongtai Liu⁵, Zhuang Tian⁵, Yanhong Wang⁶, Xiaojian Wang⁷, Mengtao Li¹ and Xiaofeng Zeng⁸, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ²Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), ⁴State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁶Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…
Abstract Number: 2247 • ACR Convergence 2024
Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
Klára Prajzlerová¹, Olga Kryštufková², Petra Hánová¹, Nora Růžičková², Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].